Form 4: Singular Genomics Systems COO Jyotsna Ghai Reports Stock Transactions
SEC Form 4 Filing
Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, reports the acquisition and disposal of company stock and restricted stock units.
Summary
- On May 9, 2024, Jyotsna Ghai, the Chief Operating Officer of Singular Genomics Systems, engaged in transactions involving the company's stock.
- Ghai acquired 7,500 shares of Common Stock through the settlement of vested Restricted Stock Units (RSUs).
- Ghai also disposed of 7,500 shares.
- Following these transactions, Ghai directly owns 10,500 shares of Common Stock.
- Ghai also holds 112,500 Restricted Stock Units (RSUs).
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions by a company insider, with no inherent positive or negative implications.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely negligible.
Key Dates
| Date | Description |
|---|---|
| 02/09/2024 | Date from which RSUs vest in 16 equal quarterly installments over four years |
| 05/09/2024 | Date of the reported stock transactions (acquisition and disposal) and RSU vesting |
| 05/13/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.